| Pharmaceutical Information |
| Drug Name |
Moxonidine |
| Drug ID |
BADD_D01503 |
| Description |
Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. As well, moxonidine has been shown to present blood pressure-independent beneficial effects on insulin resistance syndrome. |
| Indications and Usage |
For the treatment of mild to moderate essential or primary hypertension [L1025]. Effective as most first-line antihypertensives when used as monotherapy [A27137]. |
| Marketing Status |
Not Available |
| ATC Code |
C02AC05 |
| DrugBank ID |
DB09242
|
| KEGG ID |
D05087
|
| MeSH ID |
C043482
|
| PubChem ID |
4810
|
| TTD Drug ID |
D0E9PK
|
| NDC Product Code |
Not Available |
| Synonyms |
moxonidine | 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine | moxonidin | Cynt | Physiotens | Moxon | Normatens | BE 5895 | BE-5895 |
|
| Chemical Information |
| Molecular Formula |
C9H12ClN5O |
| CAS Registry Number |
75438-57-2 |
| SMILES |
CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
